Global Information
회사소개 | 문의

신경아세포종 : 파이프라인 리뷰

Neuroblastoma - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 05월 상품 코드 229754
페이지 정보 영문 543 Pages
가격
US $ 2,000 ₩ 2,257,600 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,515,200 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,772,800 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


신경아세포종 : 파이프라인 리뷰 Neuroblastoma - Pipeline Review, H1 2018
발행일: 2018년 05월 페이지 정보 : 영문 543 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

신경아세포종이란 부신·경부·흉부·척추에 있는 신경조직·신경제세포에서 유래하는 암으로, 환자의 대부분이 유아입니다. 일반적으로 부신에서 발생하여 인체의 다른 부위로 전이합니다. 질병 소질에는 유전적 조건 등이 포함되어 있습니다. 주요 증상으로 복부·흉부의 종기, 구토, 골통, 호흡 곤란, 다크서클, 이동 곤란 등을 들 수 있습니다. 진단시에는 X선 영상 검사 및 CT스캔, 핵자기 공명 영상(MRI), 생검, 요검사 등을 이용하여 검사합니다. 화학요법 및 방사선 치료, 줄기세포 이식, 모노클로널 항체 등의 의약 요법에 의해 질환을 제어할 수 있는 가능성도 있습니다.

세계 각국에서의 신경아세포종(Neuroblastoma) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

목차

서론

  • 분석 범위

신경아세포종의 개요

치료제 개발

  • 신경아세포종용 파이프라인 제품 : 개요
  • 신경아세포종용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 신경아세포종 치료제

대학/연구기관에서 연구중인 신경아세포종 치료제

파이프라인 제품의 개요

  • 후기 단계 제품
  • 임상시험 단계 제품
  • 초기 단계 제품

신경아세포종 치료제 : 개발중인 제품 리스트(기업별)

신경아세포종 치료제 : 연구중인 제품 리스트(대학/연구기관별)

신경아세포종 치료제 개발에 참여하고 있는 기업

  • Ability Pharmaceuticals, S.L.
  • Acetylon Pharmaceuticals, Inc.
  • Advanced Accelerator Applications S.A.
  • Ampio Pharmaceuticals, Inc.
  • APEIRON Biologics AG
  • AstraZeneca Plc
  • Bellicum Pharmaceuticals, Inc.
  • Bexion Pharmaceuticals, LLC. .
  • BioLineRx, Ltd.
  • Bionucleon Srl
  • Biotec Pharmacon ASA
  • Cebiotex, S.L.
  • Celgene Corporation
  • Chugai Pharmaceutical Co., Ltd.
  • Cleveland BioLabs, Inc.
  • CorMedix Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • DEKK-TEC, Inc.
  • EnGeneIC Ltd
  • Errant Gene Therapeutics, LLC
  • GlaxoSmithKline Plc
  • Green Cross Cell Corporation
  • Ignyta, Inc.
  • Incuron, LLC
  • Juno Therapeutics Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Lindis Biotech GmbH
  • MabVax Therapeutics Holdings, Inc
  • MediaPharma s.r.l.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Morphogenesis, Inc.
  • Novartis AG
  • Novogen Limited
  • Pfizer Inc.
  • Pharmacyclics, Inc.
  • Progenics Pharmaceuticals, Inc.
  • Recombio S.L
  • Ribomic Inc.
  • Sareum Holdings Plc
  • Shionogi & Co., Ltd.
  • Syros Pharmaceuticals, Inc.
  • Threshold Pharmaceuticals, Inc.
  • Tiltan Pharma Ltd.

신경아세포종 : 치료제 평가

  • 단일요법 치료제의 경우
  • 병용 치료제의 경우
  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

약제 개요

신경아세포종 치료제 : 파이프라인 제품의 최신 동향

신경아세포종 치료제 : 개발 휴지 상태의 제품

신경아세포종 치료제 : 개발이 중지된 제품

신경아세포종 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향·프레스 릴리스

부록

도표

KSA 16.06.27

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H1 2018, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 30, 15, 3, 44, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 14 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Neuroblastoma - Overview
  • Neuroblastoma - Therapeutics Development
  • Neuroblastoma - Therapeutics Assessment
  • Neuroblastoma - Companies Involved in Therapeutics Development
  • Neuroblastoma - Drug Profiles
  • Neuroblastoma - Dormant Projects
  • Neuroblastoma - Discontinued Products
  • Neuroblastoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Neuroblastoma, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H1 2018
  • Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H1 2018
  • Neuroblastoma - Pipeline by Alissa Pharma, H1 2018
  • Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H1 2018
  • Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2018
  • Neuroblastoma - Pipeline by AstraZeneca Plc, H1 2018
  • Neuroblastoma - Pipeline by Autolus Ltd, H1 2018
  • Neuroblastoma - Pipeline by Bayer AG, H1 2018
  • Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018
  • Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H1 2018
  • Neuroblastoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
  • Neuroblastoma - Pipeline by BioLineRx Ltd, H1 2018
  • Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H1 2018
  • Neuroblastoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Neuroblastoma - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2018
  • Neuroblastoma - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2018
  • Neuroblastoma - Pipeline by Cebiotex SL, H1 2018
  • Neuroblastoma - Pipeline by Celgene Corp, H1 2018
  • Neuroblastoma - Pipeline by Celldex Therapeutics Inc, H1 2018
  • Neuroblastoma - Pipeline by Cellectar Biosciences Inc, H1 2018
  • Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H1 2018
  • Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H1 2018
  • Neuroblastoma - Pipeline by CorMedix Inc, H1 2018
  • Neuroblastoma - Pipeline by Curis Inc, H1 2018
  • Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018
  • Neuroblastoma - Pipeline by DEKK-TEC Inc, H1 2018
  • Neuroblastoma - Pipeline by EnGeneIC Ltd, H1 2018
  • Neuroblastoma - Pipeline by Epizyme Inc, H1 2018
  • Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H1 2018
  • Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Neuroblastoma - Pipeline by GC Pharma, H1 2018
  • Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Neuroblastoma - Pipeline by ID Pharma Co Ltd, H1 2018
  • Neuroblastoma - Pipeline by Ignyta Inc, H1 2018
  • Neuroblastoma - Pipeline by Ipsen SA, H1 2018
  • Neuroblastoma - Pipeline by Juno Therapeutics Inc, H1 2018
  • Neuroblastoma - Pipeline by Kazia Therapeutics Ltd, H1 2018
  • Neuroblastoma - Pipeline by Loxo Oncology Inc, H1 2018
  • Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H1 2018
  • Neuroblastoma - Pipeline by MacroGenics Inc, H1 2018
  • Neuroblastoma - Pipeline by MediaPharma SRL, H1 2018
  • Neuroblastoma - Pipeline by Merck & Co Inc, H1 2018
  • Neuroblastoma - Pipeline by Morphogenesis Inc, H1 2018
  • Neuroblastoma - Pipeline by Novartis AG, H1 2018
  • Neuroblastoma - Pipeline by OGD2 Pharma SAS, H1 2018
  • Neuroblastoma - Pipeline by Pfizer Inc, H1 2018
  • Neuroblastoma - Pipeline by Phylogica Ltd, H1 2018
  • Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2018
  • Neuroblastoma - Pipeline by Recombio SL, H1 2018
  • Neuroblastoma - Pipeline by Ribomic Inc, H1 2018
  • Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H1 2018
  • Neuroblastoma - Pipeline by Sareum Holdings Plc, H1 2018
  • Neuroblastoma - Pipeline by Sierra Oncology Inc, H1 2018
  • Neuroblastoma - Pipeline by Sorrento Therapeutics Inc, H1 2018
  • Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H1 2018
  • Neuroblastoma - Pipeline by TheraBiologics Inc, H1 2018
  • Neuroblastoma - Pipeline by Trellis Bioscience Inc, H1 2018
  • Neuroblastoma - Pipeline by ZIOPHARM Oncology Inc, H1 2018
  • Neuroblastoma - Dormant Projects, H1 2018

List of Figures

  • Number of Products under Development for Neuroblastoma, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research